What they were paid
Aktis Oncology Director Compensation Table · the one fiscal year held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2023 | $19,125 | $22,506 | — | $26,372 | $68,003 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Aktis Oncology, Inc. DEF 14A filed October 8, 2024, accession 0001213900-24-086050, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2023Aktis Oncology pays directors a $140,000 cash retainer.
Committees
FY2023 · as the proxy prints themNominating/Governance · Technology
The rest of the Aktis Oncology board
FY2023 · as the company reported each| Director | Role | FY2023 total |
|---|---|---|
| Arthur E. Geiss | Independent Director | $81,395 |
| J. Michael McGuire | Independent Director | $70,006 |
| Jeffrey K. McMahon | Independent Director | $65,604 |
| Jerry D. Neal | Independent Director | $105,428 |
| Jill K. Frizzley | Independent Director | $0 |
| Kamran S. Cheema | Director | $0 |
| Matthew R. Kahn | Independent Director | $0 |
| Michelle L. Petock | Independent Director | $86,900 |
| Suzanne B. Rudy | Independent Director | $91 |
The full Aktis Oncology compensation record
free company briefThis page is one director within Aktis Oncology's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat